The physiological mechanisms by which growth hormone (somatotropin) exerts its several metabolic activities remain poorly understood. In particular, there is disagreement as to whether the diabetogenic and lipolytic activities of the hormone are intrinsic properties of the molecule or are the result of contamination with other pituitary components. The availability of recombinant-DNA-derived bovine growth hormone (rebGH) presented an opportunity to compare the biological activities of rebGH and pituitary bGH in the absence of pituitary contaminants. Pituitary bGH and rebGH were immunologically identical in the radioimmunoassay for bGH, and good agreement was obtained for the potency of the latter measured by radioimmunoassay (1.6 units/mg) and the dwarf-mouse bioassay (1.4 units/mg). The lipolytic activity in vitro was examined by measuring the release of glycerol from rat epididymal fat maintained in the presence of dexamethasone (0.2pg/ml) and the material to be tested (0.1 and 0.2mg/ml). Although two preparations of pituitary bGH stimulated a significant (P< 0.01) increase in glycerol production, neither rebGH nor recombinant-DNA-derived chicken GH was lipolytic. However, when rebGH was intravenously injected into three sheep (0.15 mg/kg), the increase in plasma nonesterified fatty acids was similar to that measured with the same dose of pituitary bGH. Insulin-tolerance tests were conducted in sheep before and after treatment with rebGH and pituitary bGH (four subcutaneous injections of 0.15mg/kg). Although the effect ofrebGH was less than that ofthe pituitary hormone, both significantly impaired the ability of insulin to lower the concentration of plasma glucose. These data suggest that the lipolytic and diabetogenic activities of bGH are intrinsic properties of the molecule. However, the lipolytic activity may only become apparent after either modification of the molecule in vivo or activation of a lipolytic intermediate.
A comparison of the growth-promoting, lipolytic, diabetogenic and immunological properties of pituitary and recombinant-DNA-derived bovine growth hormone (somatotropin) The physiological mechanisms by which growth hormone (somatotropin) exerts its several metabolic activities remain poorly understood. In particular, there is disagreement as to whether the diabetogenic and lipolytic activities of the hormone are intrinsic properties of the molecule or are the result of contamination with other pituitary components. The availability of recombinant-DNA-derived bovine growth hormone (rebGH) presented an opportunity to compare the biological activities of rebGH and pituitary bGH in the absence of pituitary contaminants. Pituitary bGH and rebGH were immunologically identical in the radioimmunoassay for bGH, and good agreement was obtained for the potency of the latter measured by radioimmunoassay (1.6 units/mg) and the dwarf-mouse bioassay (1.4 units/mg). The lipolytic activity in vitro was examined by measuring the release of glycerol from rat epididymal fat maintained in the presence of dexamethasone (0.2pg/ml) and the material to be tested (0.1 and 0.2mg/ml). Although two preparations of pituitary bGH stimulated a significant (P< 0.01) increase in glycerol production, neither rebGH nor recombinant-DNA-derived chicken GH was lipolytic. However, when rebGH was intravenously injected into three sheep (0.15 mg/kg), the increase in plasma nonesterified fatty acids was similar to that measured with the same dose of pituitary bGH. Insulin-tolerance tests were conducted in sheep before and after treatment with rebGH and pituitary bGH (four subcutaneous injections of 0.15mg/kg). Although the effect ofrebGH was less than that ofthe pituitary hormone, both significantly impaired the ability of insulin to lower the concentration of plasma glucose. These data suggest that the lipolytic and diabetogenic activities of bGH are intrinsic properties of the molecule. However, the lipolytic activity may only become apparent after either modification of the molecule in vivo or activation of a lipolytic intermediate.
The expression of bGH with additional Nterminal methionine by means of recombinant-DNA techniques has provided a potentially limitless source of the hormone to stimulate milk production in domestic ruminants (Hart, 1983) and has renewed interest in the physiological mechanism(s) by which the hormone achieves this response. Close arterial infusion of bGH into the Hart, 1983) , and attention has turned to the possibility that the hormone partitions nutrients (glucose and triacylglycerols) away from tissue deposition and makes them available for milk synthesis by exerting its diabetogenic and lipolytic properties (Hart et al., 1978; Hart, 1983; . However, there has been considerable debate over the question of whether GH is intrinsically lipolytic and/or diabetogenic.
The lipolytic activity of pituitary GH has been recognized since Lee & Schaeffer (1934) disVol. 224 covered that growth-promoting extracts of the anterior pituitary depleted fat stored in rats. As purer preparations of the hormone became available, this property of GH underwent considerable investigation to determine the role of GH in fat metabolism [see Goodman & Schwartz (1974) and Rao & Ramachandran (1977) for reviews]. More recently, evidence has accumulated to suggest that the pure hormone may not be lipolytic and that this activity is stimulated by either pituitary contaminants or cleaved forms of GH (Salaman, 1972; Assa & Laron, 1977; Schleyer & Voigt, 1977; Frigeri, 1980; Frigeri et al., 1982 Frigeri et al., , 1983 . Raben & Westermeyer (1952) were among the first to suggest that pig GH could be prepared without diabetogenic activity, and more recently homogeneous forms of hGH and bGH have been prepared which had markedly decreased diabetogenic activity (Lewis et al., 1977; Hart et al., 1984) . Lewis et al. (1977) partially purified a diabetogenic component from crude hGH (Mr < 5000), and furthermore were able to convert non-diabetogenic hGH into a diabetogenic form by proteolytic cleavage, thereby suggesting that the active material is a modified form of GH. This contention is supported by the fact that short sequences of hGH have been found to be diabetogenic in rats and rabbits (Lostroh & Krahl, 1976; Bornstein, 1978 A 40g batch of the E. coli cells containing the rebGH was suspended in 200ml of buffer (20mM-Tris/HCl/50mM-NaCl, pH 7.5) and was disrupted by three passages through a Gaulin homogenizer. The broken cells were centrifuged (7000g for 15min at 4°C), and the pellet was resuspended in 50ml of distilled water, to which 50ml of acetic acid was added over a period of 10min. The mixture was stirred for 3 h and then centrifuged (60000g for 30min at 4°C). The rebGH in the supernatant was purified by gel chromatography on a column (5cmx95cm) of Sephadex G-75 which was equilibrated with acetic acid (10%, v/v).
The fractions containing rebGH were pooled, dialysed against distilled water and redialysed against glycine/HCl (0.01 M; pH 3.6)/lactose (0.2%)/mannitol (0.2%).
The rebGH was similar to preparations of recombinant-DNA-derived hGH in that it possessed an additional methionine residue at the Nterminus (Goeddel et al., 1979) . Furthermore, it possessed leucine at position 127. The integrity of rebGH was assessed by high-pressure liquid chromatography and SDS/polyacrylamide-gel electrophoresis in the presence and absence of 2-mercaptoethanol (Hart et al., 1984) . Radioimmunoassay
The rebGH was assessed in the radioimmunoassays for ruminant GH (Hart et al., 1975) and prolactin (Hart, 1972) with modifications described by Tindal et al. (1982) .
Growth-promoting activity
The growth-promoting activity of rebGH was measured with hypopituitary dwarf mice and the method described by Wallis & Dew (1973) .
Lipolytic activity (in vitro)
This was examined by measuring glycerol production from rat epididymal fat which had been incubated for 4h in the presence of the test material and dexamethasone (Hart et al., 1984) . The activity of rebGH was examined at two concentrations (0.1 and 0.2mg/ml) and compared with two preparations of pituitary bGH prepared by the method of Ellis (1961) . A preparation of recombinant-DNA-derived chicken GH (Boone et al., 1983) was included in one of the experiments.
Intravenous injection into sheep
Four groups of three castrated male sheep (23-41 kg) were individually housed in metabolism crates and fed on a diet of concentrates and hay ad libitum. The sheep were starved for 22h before the start of the experiment, during which they were allowed access to water. On the day of the experiment, three blood samples (6ml) were taken from a jugular catheter, inserted at least 24h previously, and the stability of the pre-injection glucose values was immediately established with a Hypocount blood glucose monitor (Hypoguard Ltd., Woodbridge, Suffolk, U.K.). Each animal was then injected, via the catheter, with 3 ml of the test material (0.15mg/kg) followed by 2ml of sterile saline (0.9% NaCl). The treatments were as follows: group 1, glycine/HCl (0.01 M; pH3.6)+lactose (0.2%)+mannitol (0.2%); group 2, pituitary bGH dissolved in sterile saline (0.9%, pH 11.0), group 3, rebGH dissolved in glycine/HCl (0.01M; pH3.6) + lactose (0.2%) + mannitol (0.2%); group 4, pituitary bGH dissolved as for group 3. The pituitary bGH had been prepared by the method of Ellis (1961) and its growthpromoting activity (1.6 units/mg) determined by the dwarf-mouse assay. Blood samples (5 ml) were collected every 30min for 2h and then at 1 h intervals for up to 9h after the intravenous injection.
The plasma was stored at -20°C before analysis for GH (Hart et al., 1975; Tindal et al., 1982) , glucose, urea and NEFA (Hart et al., 1978) . Only selected samples were analysed for NEFA.
Diabetogenic activity
In this study the diabetogenic activity of rebGH was defined as its ability to impair insulin sensitivity in sheep as measured by the insulintolerance test.
Intravenous insulin-tolerance tests were carried out in three groups of four castrated male sheep which had been pre-treated (0.15mg/kg injected subcutaneously twice daily for 2 days) with the test material: group 1, pituitary bGH (1.6 units/mg) dissolved in sterile saline (0.9%, pH 11.0); group 2, pituitary bGH dissolved in glycine/HCl (0.01 M; pH3.6)+lactose (0.2%)+mannitol (0.2%); group 3, rebGH dissolved as for group 2. The sheep, which had previously been fed ad libitum, were starved for 17h before each insulin-tolerance test. On the morning of the test, four blood samples (3 ml) were taken at approx. 10 min intervals, from a jugular catheter which was inserted at least 24h previously, and the stability of the pre-insulin glucose values was established with the blood glucose monitor. Bovine insulin (0.08 unit/kg, in 2ml of sterile saline, 0.9%) was then injected via the catheter, followed by 2ml of saline. Blood samples were taken at 8min intervals for 32min after the insulin injection, and the plasma was analysed for glucose by using a Chemlab continuous-flow analyser. The results for the high-pressure liquid chromatography are illustrated in Fig. 2 and support the data obtained with SDS/polyacrylamide-gel electrophoresis. The rebGH contained no low-Mr components (i.e. Mr < 22000), but contained three high-Mr components (i.e. Mr>22 000), two of which corresponded to those found by SDS/polyacrylamide-gel electrophoresis. The pituitary bGH contained at least four peaks of Mr> 22000 and a number of low-Mr (i.e. <22000) components.
Radioimmunoassay
When compared on a weight basis, serial dilutions of rebGH were parallel with the pituitary bGH standard (NIH-GH-B2; 1.5 units/mg) in the radioimmunoassay for bovine GH (Fig. 3) . The potency of rebGH, derived from these data, was equivalent to 1.6 units/mg. In the radio- . Binding displacement characteristics in the radioimmunoassay for ruminant GH (Hart et al., 1975) , pituitary bGH (NIH-GH-B2; 1.5 units/mg); *-----, rebGH.
,-, 0. Lipolytic activity (in vitro) Fig. 4(a) shows the effect of rebGH (0.1 mg/ml) and of pituitary bGH (ICH/bGH/5; 1.2 units/mg; 0.1 mg/ml) on glycerol release from rat epididymal fat maintained in vitro. Fig. 4(b) illustrates a similar comparison using another preparation of pituitary bGH (ICH/bGH/12; 1.5 units/mg) and recombinant-DNA-derived chicken GH, but the concentration of rebGH was increased to 0.2mg/ml of medium. Vaughan (1962) had previously established that glycerol is not readily metabolized by rat adipose tissue, and thus its release can be taken as a reliable indication of the lipolytic activity of the material tested. Although both of the pituitary preparations stimulated a significant increase in glycerol production, neither the bovine nor the chicken recombinant-DNA-derived GH was lipolytic in vitro at the doses tested.
Intravenous injection into sheep
Single intravenous injection of three preparations of bGH into sheep stimulated similar changes in circulating NEFA (Fig. 5) . Pituitary bGH, dissolved in saline at pH 1.0 (group 2), stimulated a significant increase in plasma NEFA after 2h, which remained elevated for up to 7h. Similar responses were measured with rebGH (group 3) and pituitary bGH (group 4), which were dissolved in glycine/HCl, pH 3.6, but in both cases the magnitude of the average rise in NEFA was considerably less than that measured in group 2 (group 2, +0.66mM; group 3, +0.39mM; group 4, +0.36mM at 2h after injection). The initial changes in plasma glucose were different in each Time (h) group (Fig. 6 ). For groups 2 and 4, circulating glucose increased within 15min of injection and then declined to reach a trough after 60-90min. The sheep treated with rebGH (group 3) showed no initial rise in plasma glucose, but a small fall Vol. 224 was noted 30min after treatment. Thereafter all of the group exhibited an increase in glucose such that, after 3h, the average concentration of each group was significantly higher than the average pre-treatment value (group 2, +0.67mM; group 3, +0.40mM; group 4, +0.44mM; P<0.001). None of the preparations provoked significant changes in plasma urea.
Diabetogenic activity
Pre-treatment with pituitary bGH dissolved both in saline (pH 11.0) and in glycine/HCl (pH 3.6) significantly decreased the insulin sensitivity of the sheep tested ( Fig. 7; groups 1 and 2) . The rebGH was also found to be diabetogenic (group 3), but, at the dosage used, its ability to inhibit the insulin-stimulated fall in plasma glucose was somewhat less than that of the pituitary hormone.
Discussion
The data obtained from the radioimmunoassay for ruminant GH clearly indicated that pituitary bGH and rebGH were immunologically indistinguishable with this antiserum. Furthermore, the potency of rebGH, calculated from the radioimmunoassay (1.6 units/mg) was slightly tp<0.l, *P<0.05, ***P<0.001.
higher than that of the pituitary bGH standard (NIH-GH-B2, 1.5 units/mg), which has the highest biological activity of any bGH preparation distributed under the programmes of the National Institute of Arthritis Metabolism and Digestive Diseases (Reichert & Wilhelmi, 1973 , 1978 . Allowing for the precision of the dwarf-mouse assay for growth-promoting activity, good agreement was obtained between the potency of rebGH calculated from the radioimmunoassay and that derived from the bioassay (1.4 units/mg). Similar agreement was obtained for recombinant-DNAderived hGH (Goeddel et al., 1979; Olson et al., 1981) . Research in rats has suggested that GH may be modified, both before and after secretion-from the pituitary, to a form which either retains or has enhanced growth-promoting activity but cannot be detected by radioimmunoassay (see Vodian & Nicoll, 1979, for (Goodman & Schwartz, 1974; Rao & Ramachandran, 1977) . Frigeri (1980) and Frigeri et al. (1983) found that highly purified pituitary hGH and bGH failed to stimulate glycerol production from epididymal fat or adipocytes taken from starved rats and that the lipolytic activity in vitro was associated with an acidic fraction which was removed during the chromatographic purification. They further demonstrated that recombinant-DNA-derived hGH was not lipolytic when incubated with rat fat in vitro (Frigeri et al., 1982) .
Our results, with two different recombinant-DNA-derived growth hormones, support those of Frigeri and co-workers. Neither of the preparations increased glycerol production from rat epididymal fat maintained in vitro, whereas both of the pituitary preparations were markedly successful in that respect. Although it is possible that rat adipose tissue is insensitive to the lipolytic activity of highly purified bGH, it is more likely that these data support the contention that pituitary bGH, extracted by salt precipitation (Ellis, 1961) , contains either modified lipolytic forms of bGH, which may be the result of proteolytic cleavage before or during extraction, or other lipolytic pituitary factors. In this respect it is relevant that the pituitary bGH used in this study contained lowMr components (i.e. <22000), which were absent from rebGH. Furthermore, it has been shown that commercially available preparations of hGH contain substantial quantities of f-and a-lipotropin (Kuhn et al., 1983) .
Intravenous injection of pituitary bGH stimulated a rise in plasma NEFA which was similar to that previously found by others (Williams et al., 1963; Bassett & Wallace, 1966) (Bornstein et al., 1983) .
It should be noted that our results and those of Frigeri et al. (1982) do not agree with data obtained by Goodman & Grichting (1983) and Goodman (1984) , who demonstrated an increase in glycerol production from rat epididymal fat maintained in vitro with both highly purified hGH and recombinant-DNA-derived hGH. It is difficult to account for these disparate results; a possible explanation might be that the last group used fed rats in their studies, whereas the other two groups used rats which had been starved for 48 h. Ruiz et al. (1981) have shown that the lipolytic response of rat tissue can be influenced by prior feeding, and recombinant-DNA-derived hGH was found to stimulate lipolysis weakly in fat taken from fed rats, but the response was not dose-related (Frigeri et al., 1982) .
Similar controversy surrounds the diabetogenic activity of bGH (Lewis et al., 1980) . The changes in plasma glucose after intravenous injection of pituitary bGH and rebGH into sheep, combined with the results of the insulin-tolerance test, conclusively indicated that, although the diabetogenic activity of rebGH may be slightly decreased, the hormone can be regarded as intrinsically diabetogenic. This agrees with data in which the diabetogenic activity of recombinant-DNA-derived hGH was examined by using oral glucosetolerance tests in humans (Rosenfeld et al., 1982) . The plasma glucose response to the intravenous injection of pituitary bGH was similar to that found by Bassett & Wallace (1966) . It was noteworthy that the increased plasma glucose was associated with the decreased insulin tolerance. In other experiments, in which non-diabetogenic forms of bGH have been examined (Hart et al., 1984) , neither of these responses occurred (I. C. Hart, unpublished work), which suggests that the increased circulating glucose is the result of a decrease in the rate of its uptake by body tissues rather than the hormone stimulating glycogenolysis or gluconeogenesis.
The lack of a technique in vitro for examining diabetogenic activity prevented us from obtaining further information on the form of the hormone which stimulates this response. However, the conversion of the molecule into a diabetogenic peptide is a likely possibility, as short sequences of hGH are diabetogenic in rats and rabbits (Lostroh & Krahl, 1976; Bornstein, 1978) . Furthermore, Lewis et al. (1977 Lewis et al. ( , 1980 have increased the diabetogenic activity of purified hGH by proteolytic cleavage with subtilisin and have partially purified a diabetogenic component from crude hGH which has a M, of less than 5000. The present data do not support the contention that GH can be purified to the point where it is no longer diabetogenic in vivo. Preparations ofhGH and bGH have been isolated which were growth-promoting but exhibited no diabetogenic activity in three different test systems in vivo (Lewis et al., 1977; Hart et al., 1984) . Although both preparations had the physical and chemical properties of monomeric GH, the possibility should now be considered that they may have undergone conversion into a nondiabetogenic form of the hormone either before or after extraction from the pituitary.
In conclusion, these results show that the lipolytic and diabetogenic properties of bGH are not the result ofcontamination with other pituitary factors, but are derived from the bGH molecule. It remains to be seen whether the activities are stimulated by bGH itself, or by proteolytically cleaved forms of the molecule, or whether the hormone activates lipolytic or diabetogenic intermediates in vivo.
